Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Total Liabilities (2019 - 2026)

Atea Pharmaceuticals' Total Liabilities history spans 8 years, with the latest figure at $33.4 million for Q1 2026.

  • Quarterly Total Liabilities rose 15.54% to $33.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $33.4 million through Mar 2026, up 15.54% year-over-year, with the annual reading at $39.8 million for FY2025, 54.2% up from the prior year.
  • Total Liabilities came in at $33.4 million for Q1 2026, down from $39.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $48.7 million in Q1 2024 to a low of $19.9 million in Q1 2023.
  • The 5-year median for Total Liabilities is $28.9 million (2025), against an average of $31.0 million.
  • Year-over-year, Total Liabilities crashed 91.07% in 2022 and then skyrocketed 143.91% in 2024.
  • Atea Pharmaceuticals' Total Liabilities stood at $26.1 million in 2022, then skyrocketed by 52.19% to $39.8 million in 2023, then crashed by 35.13% to $25.8 million in 2024, then surged by 54.2% to $39.8 million in 2025, then fell by 16.13% to $33.4 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Total Liabilities are $33.4 million (Q1 2026), $39.8 million (Q4 2025), and $27.2 million (Q3 2025).